These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10091422)

  • 1. Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase.
    Russo D; Marin L; Bertone A; Tiribelli M; Testoni N; Martinelli G
    Haematologica; 1999 Feb; 84(2):185-7. PubMed ID: 10091422
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon-alpha and cytosine arabinoside therapy in chronic myeloid leukemia.
    Ezaki K
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():279-84. PubMed ID: 10895166
    [No Abstract]   [Full Text] [Related]  

  • 3. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia].
    Tóthová E; Fricová M; Stecová N; Kafková A; Mudronová B; Svorcová E; Guman T; Raffac S; Hlebasková M
    Cas Lek Cesk; 2000 Jul; 139(14):437-9. PubMed ID: 11048406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Anstrom KJ; Reed SD; Allen AS; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2584-92. PubMed ID: 15493041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
    Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
    Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of retinoic acid on the cytogenetic remission in the first chronic phase of chronic myeloid leukemia treated with interferon].
    Egyed M; Mihályfalvi Z; Kollár B; Rumi G; Keller E; Vass J; Fekete S
    Orv Hetil; 2001 Nov; 142(44):2421-5. PubMed ID: 11766235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic myelogenous leukemia].
    Ohnishi K
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1199-205. PubMed ID: 11579630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
    Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ATRA (all-trans retinoic acid) in chronic myeloid leukemia?].
    Rák K
    Orv Hetil; 2002 Jun; 143(23):1449-50; author reply 1450. PubMed ID: 12132331
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon.
    Cervantes F; Sureda A; Hernández-Boluda JC; Martino R; Brunet S; Borrego D; Antich JL; Montserrat E
    Haematologica; 2001 Dec; 86(12):1281-6. PubMed ID: 11726320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing treatment for chronic myeloid leukemia.
    Goldman JM
    N Engl J Med; 1997 Jul; 337(4):270-1. PubMed ID: 9227935
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group.
    Guilhot F
    Semin Hematol; 1993 Jul; 30(3 Suppl 3):24-5. PubMed ID: 8235700
    [No Abstract]   [Full Text] [Related]  

  • 15. Two siblings with chronic myelogenous leukemia.
    Kapsali E; Tsiara S; Christou L; Panteli A; Bourantas KL
    J Exp Clin Cancer Res; 2000 Dec; 19(4):541-3. PubMed ID: 11277336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy.
    Shah M; Jenis EH; Mookerjee BK; Schriber JR; Baer MR; Herzig GP; Wetzler M
    Cancer; 1998 Nov; 83(9):1938-46. PubMed ID: 9806652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
    Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
    Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
    Colla S; Sammarelli G; Voltolini S; Crugnola M; Sebastio P; Giuliani N
    Haematologica; 2004 May; 89(5):611-3. PubMed ID: 15136228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
    Alimena G; Breccia M; Luciano L; Quarantelli F; Diverio D; Izzo B; De Angelis B; Mancini M; Latagliata R; Carmosino I; Nanni M; Picardi M; Rotoli B; Mandelli F; Pane F
    Leuk Res; 2008 Feb; 32(2):255-61. PubMed ID: 17692911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic impact of alpha interferon in chronic myelogenous leukaemia].
    Tolo-Diebkilé A; Koffi KG; Sawadogo GD; Ndiaye FS; Nanho DC; Sékongo YM; Kouakou B; Méité N; Ayemou R; Sanogo I
    Mali Med; 2010; 25(1):22-7. PubMed ID: 21436004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.